SOURCE: Atossa Genetics Inc

Atossa Genetics Inc

October 06, 2014 08:00 ET

Atossa Genetics to Present at the 13th Annual BIO Investor Forum October 8, 2014

SEATTLE, WA--(Marketwired - Oct 6, 2014) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that Kyle Guse, CFO and General Counsel, will be a featured presenter at the 13th Annual BIO Investor Forum on October 8, 2014 a 3:00 PM at the Palace Hotel in San Francisco, CA, in the Sea Cliff Room.

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One meetings.

About Atossa Genetics

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For additional information, please visit

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, including the outcome of the FDA re-inspection completed on March 14, 2014, the outcome or timing of regulatory clearances, Atossa's ability to continue to manufacture and sell its products in a timely fashion, recalls of products, the efficacy of Atossa's products and services, performance of distributors, whether Atossa can launch in the United States and foreign markets it tests, devices and therapeutics in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.